Among diabetes drugs, GLP-1 receptor agonists and SGLT2 inhibitors were associated with greater reduction in the risk for Alzheimer’s disease (AD) than DPP-4 inhibitors, new research showed. “GLP-1 ...

A large real-world study shows lower all-cause mortality and some cardiovascular outcomes with combination therapy; other outcomes lack statistical precision.

A large McGill University study has found that two classes of medications commonly prescribed for Type 2 diabetes, both incretin-based, are associated with a reduced risk of dementia. Drawing on ...

Obesity therapeutics now represent ~$98B and 4.6% share, climbing to the fourth-largest category, with ~190 pipeline assets ...

When diabetes causes CKD, it’s sometimes called diabetic kidney disease. Elevated blood sugar levels that result from diabetes can damage the tiny blood vessels inside your kidneys. As a result, your ...

Type 2 diabetes occurs when the body does not use insulin effectively or does not produce enough insulin to maintain healthy blood sugar levels. Medications aim to lower blood glucose, reduce A1C, and ...

A new study links GLP-1 drugs, used for diabetes and weight loss, to a higher risk of erectile dysfunction.

A large cohort study found three popular GLP-1-based diabetes drugs -- semaglutide, dulaglutide, and tirzepatide -- carry similar risks for serious adverse GI events, with a rate of about 12 per 1,000 ...

People with type 2 diabetes who receive comprehensive medication reviews (CMRs) had better adherence with oral antidiabetic drugs and statin utilization compared to those who did not receive CMRs, a ...